ANTENGENE CORPORATION

ANTENGENE CORPORATION (referred to as "Antengene", Hong Kong Stock Exchange stock code: 6996.HK) is a leading biopharmaceutical company driven by research and development, dedicated to providing the most advanced therapies for patients in the Asia-Pacific region and around the world to treat cancer and other life-threatening diseases. Since its official operation in 2017, Antengene has built a rich product pipeline extending from preclinical to clinical stages through collaboration and self-research. Currently, Antengene has 15 products under development, of which 5 products have Asia-Pacific rights including the Greater China market, and 10 products have global rights. Antengene has obtained 19 clinical trial applications (IND) in multiple Asia-Pacific markets and the United States, and submitted 6 new drug applications (NDA), among which Selinexor has been granted priority approval for new drug listing in South Korea. With the vision of "Borderless Doctors, Endless Innovation," Antengene will focus on the early-stage R&D, clinical research, drug production, and commercialization of first-in-class and best-in-class therapies to address unmet clinical needs.